18 results
8-K
LRMR
Larimar Therapeutics Inc
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
the lives of patients with rare disorders through innovative gene therapies. Mr. Thomas served as Chief Operating Officer and Chief Financial Officer
DEFM14A
LRMR
Larimar Therapeutics Inc
29 Apr 20
Proxy related to merger
3:20pm
the lives of patients with rare disorders through innovative gene therapies. Mr. Thomas served as Chief Operating Officer and Chief Financial Officer
PRER14A
t6h4uqpikd6
10 Apr 20
Preliminary revised proxy
4:38pm
PREM14A
yb47qvt997 57npys
6 Mar 20
Preliminary proxy related to merger
5:32pm
8-K
EX-99.1
l0icwj wq478w
13 Jan 20
Regulation FD Disclosure
7:17am
DEFA14A
EX-99.1
p1q14us7hhjlo
13 Jan 20
Additional proxy soliciting materials
7:15am
DEFA14A
5fokye9gms6ixe
18 Dec 19
Additional proxy soliciting materials
4:31pm
8-K
EX-99.2
g4uttu1pmw1 e7
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
8-K
EX-99.1
vvbrmebag1v9vzmpp
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-99.1
lrj 11net
18 Dec 19
Additional proxy soliciting materials
8:11am
DEFA14A
EX-99.2
0drkbe486lpt8unhn
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
obht8av
17 Jan 19
Zafgen Announces Positive Results for Second Cohort
7:30am
8-K
EX-99.1
ckbcqji
25 Jun 18
Zafgen Announces Positive Full Results in Phase 2Proof-of-Concept Trial ofZGN-1061 in Patients withDifficult-to-Control Type 2 Diabetes
7:15am
8-K
EX-99.1
o94plqom
12 Jan 15
Other Events
12:00am
- Prev
- 1
- Next